**Supplementary Table 4**. SNPs with a nominal *p* value below 0.05 according to phenotype for primary and secondary analysis.

**Primary analysis – QTc absolute value**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SNP** | **Non-interaction** | **SNP x mod-high risk meds** | **SNP x low risk meds** | **SNP x tot risk meds** |
| rs10808071 | BETA=-19.48, SE=9.18, L95;U95=-37.47;-1.49, p=0.038 | BETA=-32.40, SE=11.59, L95;U95=-55.11;-9.68, p=0.007 | \ | \ |
| rs10918951 | \ | BETA=-37.61, SE=17.03, L95;U95=-70.98;-4.24, p=0.031 | \ | \ |
| rs10918952 | \ | BETA=-37.61, SE=17.03, L95;U95=-70.98;-4.24, p=0.031 | \ | \ |
| rs7155549 | \ | \ | BETA=22.94 SE=8.95, L95;U95=5.39;40.49, p=0.013 | BETA=21.60 SE=9.51, L95;U95=2.96;40.24, p=0.027 |
| rs7142881 | \ | \ | BETA=18.24 SE=7.89, L95;U95=2.19;33.40, p=0.0029 | BETA=19.52 SE=8.78, L95;U95=2.31;36.74, p=0.030 |
| rs35334661 | \ | \ | BETA=17.80 SE=7.96, L95;U95=2.78;33.70, p=0.024 | BETA=18.83 SE=8.84, L95;U95=1.52;36.15, p=0.037 |
| rs3865392 | \ | \ | BETA=15.52 SE=7.41, L95;U95=0.99;30.04, p=0.041 | BETA=18.21 SE=8.08, L95;U95=2.38;34.05, p=0.028 |
| rs4799916 | \ | \ | BETA=15.52 SE=7.41, L95;U95=0.99;30.04, p=0.041 | BETA=18.21 SE=8.08, L95;U95=2.38;34.05, p=0.028 |
| rs4799917 | \ | \ | BETA=15.52 SE=7.41, L95;U95=0.99;30.04, p=0.041 | BETA=18.21 SE=8.08, L95;U95=2.38;34.05, p=0.028 |
| rs4799915 | \ | \ | BETA=15.52 SE=7.41, L95;U95=0.99;30.04, p=0.041  | BETA=18.21 SE=8.08, L95;U95=2.38;34.05, p=0.028 |
| rs11628819 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs11621036 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs11620949 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs2165814 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs7143323 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs4981868 | \ | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs4981869 |  | \ | BETA=19.17 SE=9.28, L95;U95=0.98;37.36, p=0.043 | \ |
| rs12029454 | \ | \ | \ | BETA=50.27 SE=18.45, L95;U95=14.11;86.42, p=0.009 |
| rs767462 | \ | \ | \ | BETA=105.00 SE=40.14, L95;U95=26.30;183.60, p=0.011 |
| rs604760 | \ | \ | \ | BETA=26.97 SE=11.62, L95;U95=4.19;49.75, p=0.024 |
| rs521409 | \ | \ | \ | BETA=26.97 SE=11.62, L95;U95=4.19;49.75, p=0.024 |

**Primary analysis – QTc > median**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SNP** | **Non-interaction** | **SNP x mod-high risk meds** | **SNP x low risk meds** | **SNP x tot risk meds** |
| rs10808071 | OR=0.20, SE=0.62, L95;U95=0.06;-0.69, p=0.010 | OR=0.05, SE=1.23, L95;U95=0.004;0.58, p=0.016 | \ | \ |
| rs2834486 | OR=0.37, SE=0.49, L95;U95=0.06;-0.96, p=0.042 | \ | \ | \ |
| rs6948860 | OR=13.47, SE=1.29, L95;U95=1.08;-168.90, p=0.044 | \ | \ | \ |
| rs12143842 | OR=0.35, SE=0.52, L95;U95=0.95;-7.69, p=0.045 | \ | \ | \ |
| rs12084981 | \ | OR=0.23, SE=0.66, L95;U95=0.06;0.85, p=0.028 | \ | \ |
| rs554346 | \ | \ | OR=7.40, SE=0.88, L95;U95=1.31;41.84, p=0.024 | \ |
| rs687775 | \ | \ | OR=5.47, SE=0.81, L95;U95=1.11;26.96, p=0.037 | \ |
| rs583037 | \ | \ | OR=5.10, SE=0.82, L95;U95=1.03;25.22, p=0.046 | \ |
| rs3865392 | \ | \ | \ | OR=4.28, SE=0.61, L95;U95=1.29;14.16, p=0.017 |
| rs4799916 | \ | \ | \ | OR=4.28, SE=0.61, L95;U95=1.29;14.16, p=0.017 |
| rs4799917 | \ | \ | \ | OR=4.28, SE=0.61, L95;U95=1.29;14.16, p=0.017 |
| rs4799915 | \ | \ | \ | OR=4.28, SE=0.61, L95;U95=1.29;14.16, p=0.017 |
| rs554346 | \ | \ | \ | OR=16.11, SE=1.25, L95;U95=1.38;187.70, p=0.026 |
| rs928740 | \ | \ | \ | OR=8.04, SE=0.95, L95;U95=1.24;52.11, p=0.029 |
| rs35334661 | \ | \ | \ | OR=3.37, SE=0.58, L95;U95=1.08;10.54, p=0.037 |
| rs3807377 | \ | \ | \ | OR=6.75, SE=0.92, L95;U95=1.11;40.99, p=0.038 |
| rs7155549 |  | \ | \ | OR=3.70, SE=0.65, L95;U95=1.04;13.21, p=0.044 |
| rs7142881 | \ | \ | \ | OR=3.14, SE=0.57, L95;U95=1.02;9.70, p=0.046 |
| rs687775 | \ | \ | \ | OR=10.68, SE=1.19, L95;U95=1.03;110.50, p=0.047 |

**Secondary analysis – QTc percentage change**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **SNP** | **Non-interaction** | **SNP x mod-high risk meds** | **SNP x low risk meds** | **SNP x tot risk meds** |
| rs2834491 | BETA=-12.18, SE=5.16, L95;U95=-22.29;-2.07, p=0.036 | \ | \ | \ |
| rs150647969 | \ | BETA=19.22, SE=4.58, L95;U95=10.25;28.18, p=0.001 | \ | \ |
| rs3807370 | \ | BETA=9.01, SE=2.99, L95;U95=3.16;14.87, p=0.012 | \ | BETA=0.21 SE=3.67, L95;U95=2.03;16.40, p=0.029 |
| rs11088286 | \ | BETA=12.32, SE=4.81, L95;U95=2.90;21.74, p=0.026 | \ | \ |
| rs2070359 | \ | BETA=13.73 SE=5.73, L95;U95=2.49;24.96, p=0.036 | \ | \ |
| rs2072413 | \ | \ | \ | BETA=15.76 SE=5.48, L95;U95=5.02;26.50, p=0.015 |